Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
BMC Infect Dis ; 23(1): 639, 2023 Sep 28.
Artigo em Inglês | MEDLINE | ID: mdl-37770836

RESUMO

BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3-5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.


Assuntos
Meningite , Vancomicina , Humanos , Vancomicina/uso terapêutico , Meropeném/uso terapêutico , Cefepima/uso terapêutico , Ceftazidima/uso terapêutico , Estudos Retrospectivos , Antibacterianos/uso terapêutico , Meningite/tratamento farmacológico , Bactérias , Staphylococcus , Atenção à Saúde , Ampicilina
2.
Expert Rev Anti Infect Ther ; 12(3): 333-42, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24512210

RESUMO

Among hospital-associated infections, healthcare-associated central nervous system infections are quite important because of high morbidity and mortality rates. The causative agents of healthcare-associated meningitis differ according to the status of immune systems and underlying diseases. The most frequent agents are Gram-negative bacilli (Pseudomonas spp., Acinetobacter spp., Escherichia coli and Klebsiella pneumoniae) and Gram-positive cocci (Staphylococcus aureus and coagulase-negative staphylococci). There are currently several problems in the treatment strategies of healthcare-associated meningitis due to a globally increasing resistance problem. Strategies targeting multidrug-resistant pathogens are especially limited. This review focuses on healthcare-associated meningitis and the current treatment strategies with a particular focus on methicillin-resistant Staphylococcus aureus (MRSA) meningitis.


Assuntos
Infecção Hospitalar/tratamento farmacológico , Meningites Bacterianas/tratamento farmacológico , Antibacterianos/uso terapêutico , Líquido Cefalorraquidiano/microbiologia , Infecção Hospitalar/diagnóstico , Infecção Hospitalar/microbiologia , Infecção Hospitalar/mortalidade , Farmacorresistência Bacteriana , Bactérias Gram-Negativas/efeitos dos fármacos , Cocos Gram-Positivos/efeitos dos fármacos , Humanos , Meningites Bacterianas/diagnóstico , Meningites Bacterianas/microbiologia , Meningites Bacterianas/mortalidade , Testes de Sensibilidade Microbiana , Fatores de Risco , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/tratamento farmacológico
3.
Surg Infect (Larchmt) ; 14(4): 357-62, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23672240

RESUMO

BACKGROUND: Vancomycin is the mainstay of treatment for methicillin-resistant Staphylococcus aureus (MRSA) meningitis. However, successful outcomes with linezolid have not been reported in a large series of patients. We conducted a single-center retrospective cohort study to compare vancomycin with linezolid in the treatment of MRSA meningitis. METHODS: We extracted data and outcomes for all adult patients (age >18 years) with culture-proved MRSA meningitis who received vancomycin or linezolid between January 2006 and June 2011. A definite diagnosis of meningitis was based on the isolation of MRSA in at least one cerebrospinal fluid (CSF) culture and findings in CSF that are typical of the infection. Linezolid was given intravenously (IV) at a dosage of 600 mg q12h and vancomycin IV at 500 mg q6h. RESULTS: A total of 8 patients with MRSA meningitis (5 male, 3 female; age [mean±SD] 61.6±13.2 years) received vancomycin and 9 patients (7 male, 2 female; age 59.1±15.6 years) received linezolid. All isolated strains of MRSA were susceptible to both vancomycin and linezolid. The rates of microbiologic success with linezolid or vancomycin, in terms of clearance of MRSA from CSF on day 5, were 7/9 and 2/8 (p=0.044, Fisher exact test). No severe adverse events occurred in either treatment arm of the study. One-month survival of the patients in whom treatment was successful microbiologically was 2/2 in the vancomycin-treated group and 4/7 in the linezolid-treated group. Minimum inhibitory concentration (MIC) data for vancomycin were available for 5/6 treatment failures with vancomycin, and vancomycin MIC values of these five strains were 2 mg/L. CONCLUSION: Analysis of the findings in the limited cohorts in our study suggests that linezolid is superior to vancomycin for treating MRSA meningitis, especially in cases in which there is a high MIC (2 mg/L) for vancomycin. A clinical study involving larger cohorts may increase the evidence available in relation to this question.


Assuntos
Acetamidas/uso terapêutico , Antibacterianos/uso terapêutico , Meningites Bacterianas/tratamento farmacológico , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Oxazolidinonas/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Vancomicina/uso terapêutico , Acetamidas/efeitos adversos , Adulto , Idoso , Antibacterianos/efeitos adversos , Estudos de Coortes , Feminino , Humanos , Linezolida , Masculino , Meningites Bacterianas/microbiologia , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Oxazolidinonas/efeitos adversos , Estudos Retrospectivos , Infecções Estafilocócicas/microbiologia , Resultado do Tratamento , Vancomicina/efeitos adversos
4.
Antimicrob Agents Chemother ; 57(3): 1556-8, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23318792

RESUMO

In this study, we aimed to compare the antibacterial activities of daptomycin and vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) meningitis (induced by MRSA strain ATCC 43300) in an experimental rabbit meningitis model. After an 8-h period of treatment, bacterial counts decreased significantly in both treatment groups compared to the control group (P < 0.05). However, there was no statistically significant difference between treatment groups. Our results suggest that the antibacterial activity of daptomycin is similar to vancomycin for treatment in the experimental MRSA meningitis model in rabbits.


Assuntos
Antibacterianos/farmacologia , Daptomicina/farmacologia , Meningites Bacterianas/tratamento farmacológico , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Infecções Estafilocócicas/tratamento farmacológico , Vancomicina/farmacologia , Animais , Contagem de Colônia Microbiana , Modelos Animais de Doenças , Meningites Bacterianas/complicações , Meningites Bacterianas/microbiologia , Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento , Testes de Sensibilidade Microbiana , Coelhos , Infecções Estafilocócicas/complicações , Infecções Estafilocócicas/microbiologia
5.
Turkiye Parazitol Derg ; 36(2): 71-4, 2012.
Artigo em Turco | MEDLINE | ID: mdl-22801909

RESUMO

OBJECTIVE: In this study, 5073 fecal specimens and cellophane tapes from patients were examined during the period of May 1, 2009-April 30, 2010 in the parasitology laboratory of the Ege University Medical School. METHODS: Sticky tape test and ethyl acetate sedimentation methods, saline, iodine, modified kinyoun's acid-fast, Trichrome, modified Trichrome and giemsa staining procedures have been applied to the stool samples. RESULTS: After the macroscopic and microscopic examinations, 1138 (22.43%) intestinal parasites were determined. Cryptosporidium spp. (n=381; 33.47%), Blastocystis hominis (n=368; 32.33%) and Cyclospora spp. (n=187; 16.43%) were the three most common parasites obtained during the examination. The most commonly determined helminth was Enterobius vermicularis (n=33; 2.89%). CONCLUSION: Detection of Microsporidium spores in immununosuppressed patients showed also the importance of specific staining methods. Intestinal parasites are causing serious public health problems in our region.


Assuntos
Fezes/parasitologia , Enteropatias Parasitárias/diagnóstico , Enteropatias Parasitárias/epidemiologia , Animais , Blastocystis hominis/isolamento & purificação , Cryptosporidium/isolamento & purificação , Cyclospora/isolamento & purificação , Enterobius/isolamento & purificação , Humanos , Prevalência , Coloração e Rotulagem , Turquia/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA